- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 379KB)
Epcoritamab – November 2024
Epcoritamab; Solution concentrate for subcutaneous injection 4 mg in 0.8 mL, Solution for subcutaneous injection 48 mg in 0.8 mL; Epkinly®
Last updated
30 May 2025